Mark Marriott
Overview
Explore the profile of Mark Marriott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1697
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923190
Introduction: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used...
2.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923189
Introduction: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. There were 33 335 people with MS in Australia in 2021 and 2917...
3.
Evrard C, El Attaoui A, Pistea C, Enache I, Marriott M, Mayaud L, et al.
Sensors (Basel)
. 2025 Jan;
25(1.
PMID: 39796917
The continuous monitoring of oxygen saturation (SpO) and respiratory rates (RRs) are major clinical issues in many cardio-respiratory diseases and have been of tremendous importance during the COVID-19 pandemic. The...
4.
Monif M, Sequeira R, Muscat A, Stuckey S, Sanfilippo P, Minh V, et al.
Clin Immunol
. 2024 Jul;
265:110304.
PMID: 38964633
Cladribine (Mavenclad®) is an oral treatment for relapsing remitting MS (RRMS), but its mechanism of action and its effects on innate immune responses in unknown. This study is a prospective...
5.
Pang V, Seery N, Wesselingh R, Yeh W, Zhong M, Tan T, et al.
Mult Scler Relat Disord
. 2023 Dec;
81:105147.
PMID: 38043368
Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression in multiple sclerosis (MS) patients. Prior to the...
6.
Li V, Roos I, Monif M, Malpas C, Roberts S, Marriott M, et al.
Mult Scler Relat Disord
. 2022 Jun;
63:103913.
PMID: 35661564
Background: The coronavirus disease 2019 (COVID-19) pandemic has precipitated expansion of telemedicine in outpatient management of chronic diseases including multiple sclerosis (MS). Studies conducted pre-pandemic, when telehealth was an alternative...
7.
Seneviratne S, Marriott M, Ramanathan S, Yeh W, Brilot-Turville F, Butzkueven H, et al.
BMC Neurol
. 2022 Mar;
22(1):84.
PMID: 35264149
Background: Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD) is most classically associated in both children and adults with phenotypes including bilateral and recurrent optic neuritis (ON) and transverse myelitis (TM), with...
8.
Kunchok A, Malpas C, Nytrova P, Kubala Havrdova E, Alroughani R, Terzi M, et al.
Mult Scler Relat Disord
. 2019 Dec;
38:101868.
PMID: 31877445
Background: Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG+NMOSD are typically measured by relapse rate and disability. Using...
9.
Ramachandran P, Chan E, Poon M, Tu H, Davis J, Eisen D, et al.
J Clin Neurosci
. 2017 Mar;
41:86-87.
PMID: 28347683
No abstract available.
10.
Broadley S, Barnett M, Boggild M, Brew B, Butzkueven H, Heard R, et al.
Med J Aust
. 2015 Jul;
203(3):139-41, 141e.1.
PMID: 26224184
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition...